ZP6590 / Zealand Pharma - LARVOL DELTA

A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Zealand Pharma

First-in-human • New P1 trial • Genetic Disorders • Obesity

ZP6590-26033: A single and multiple dose trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of ZP6590 (clinicaltrialsregister.eu) - P1 | N=88 | Not yet recruiting | Sponsor: Zealand Pharma A/S

New P1 trial

Research - strengthening our engine and expanding capabilities to fuel clinical pipeline (GlobeNewswire) - "In 2026, Zealand Pharma expects to progress its GIP analog, ZP6590, into clinical development with a first-in-human clinical trial."

First-in-human • New trial • Obesity

Zealand Pharma Announces Financial Results for the First Half of 2023 (GlobeNewswire) - "ZP6590, GIP analog. Zealand expects to complete pre-clinical activities in 2023 and advance this program into first-in-human clinical trials in the first half of 2024."

New P1 trial • Metabolic Disorders • Obesity